215655-29-1 Usage
Uses
Used in Pharmaceutical Industry:
N~1~-[4-(trifluoromethyl)-2-pyrimidinyl]-1,2-ethanediamine is used as a therapeutic agent for the treatment of certain types of myelofibrosis and polycythemia vera. It serves to control the overproduction of blood cells by inhibiting the activity of Janus kinases (JAKs), which are key enzymes in blood cell production. This action helps to alleviate symptoms associated with these conditions and improve the quality of life for affected patients.
Used in Blood Disorder Management:
N~1~-[4-(trifluoromethyl)-2-pyrimidinyl]-1,2-ethanediamine is used as a JAK inhibitor for managing blood disorders characterized by the overproduction of blood cells. By blocking the JAK enzymes, ruxolitinib effectively reduces spleen size and improves symptoms in patients with myelofibrosis and polycythemia vera, making it a valuable treatment option for these conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 215655-29-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,5,6,5 and 5 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 215655-29:
(8*2)+(7*1)+(6*5)+(5*6)+(4*5)+(3*5)+(2*2)+(1*9)=131
131 % 10 = 1
So 215655-29-1 is a valid CAS Registry Number.
215655-29-1Relevant academic research and scientific papers
Identification and validation of small molecule modulators of the NusB-NusE interaction
Cossar, Peter J.,Ma, Cong,Gordon, Christopher P.,Ambrus, Joseph I.,Lewis, Peter J.,McCluskey, Adam
supporting information, p. 162 - 167 (2016/12/27)
Formation of highly possessive antitermination complexes is crucial for the efficient transcription of stable RNA in all bacteria. A key step in the formation of these complexes is the protein-protein interaction (PPI) between N-utilisation substances (Nu
SUBSTITUTED 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS GSK-3 INHIBITORS
-
Page/Page column 26, (2010/02/11)
The invention relates to compounds of formula (I) prodrugs thereof, and the pahrmaceutically acceptabel salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.
Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
-
Page/Page column 11, (2010/02/08)
The present invention provides compounds of formula (I) the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein Ra, Rb, R1, and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.
